President Trump on Tuesday issued a memorandum directing the FDA and HHS to crack down on misleading direct-to-consumer prescription drug ads, requiring clearer disclosure of risks and ensuring that promotions don't overstate benefits or push costly drugs over generics. Longtime Slashdot reader sinij shares an excerpt from the memorandum: The Secretary of Health and Human Services shall therefore take appropriate action to ensure transparency and accuracy in direct-to-consumer prescription drug advertising, including by increasing the amount of information regarding any risks associated with the use of any such prescription drug required to be provided in prescription drug advertisements, to the extent permitted by applicable law. The Commissioner of Food and Drugs shall take appropriate action to enforce the Federal Food, Drug, and Cosmetic Act's prescription drug advertising provisions, and otherwise ensure truthful and non-misleading information in direct-to-consumer prescription drug advertisements. "Advertising dollars is a major avenue for pharmaceutical companies to influence news and attempt to shape public opinion," comments sinij. "Advertising was a major contributor to painkiller addiction, where networks were hesitant to cover early reports of addictiveness. It is likely directly contributing today to lack of critical coverage of Ozempic. It is just too big of a conflict of interest to allow to stand."Read more of this story at Slashdot.